68 Results

People

  1. Schwartz
    Schwartz
  2. Motwani
    Motwani
  3. Kelsen
    Kelsen
  4. Gonen
    Gonen
  5. O'Reilly
    O'Reilly
  6. Saltz
    Saltz
  7. Lefkowitz
    Lefkowitz
  8. Shah
    Shah
  9. Carvajal
    Carvajal
  10. Ilson
    Ilson

Groups

  1. Department of Medicine (40)
  2. Solid Tumor Oncology Division (26)
  3. Hematologic Malignancies, Division of (19)
  4. Center for Pancreatic Cancer Research (14)
  5. Center for Hematologic Malignancies (13)
  6. Gastrointestinal Oncology Service (13)
  7. GSK Faculty (12)
  8. Biostatistics Service (11)
  9. Epidemiology and Biostatistics (11)
  10. Melanoma Disease Management Team (10)
  1. "piperidines"
Formats
  1. Journal Article (61)
  2. Review (4)
  3. Editorial (2)
  4. Conference Paper (1)
Groups
  1. Department of Medicine (40)
  2. Solid Tumor Oncology Division (26)
  3. Hematologic Malignancies, Division of (19)
  4. Center for Pancreatic Cancer Research (14)
  5. Center for Hematologic Malignancies (13)
  6. Gastrointestinal Oncology Service (13)

More Groups

People
  1. Gary Schwartz (23)
  2. Monica Motwani (9)
  3. David Kelsen (8)
  4. Eileen O'Reilly (7)
  5. Mithat Gonen (7)
  6. Leonard Saltz (6)

More People

Years
  1. 2025 (2)
  2. 2024 (14)
  3. 2022 (10)
  4. 2021 (1)
  5. 2017 (1)
  6. 2014 (1)

More Years

Publications
  1. Clinical Cancer Research (14)
  2. Journal of Clinical Oncology (8)
  3. Cancer Research (4)
  4. Blood (3)
  5. Annals of Oncology (2)
  6. British Journal of Haematology (2)

More Publications

Publishers
  1. American Association for Cancer Research (20)
  2. American Society of Clinical Oncology (8)
  3. Springer (5)
  4. Elsevier Inc. (4)
  5. American Society of Hematology (3)
  6. Nature Publishing Group (3)

More Publishers

Results (68)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
    Editorial

    Chi, K. N.; Rathkopf, D.; Smith, M. R.; Efstathiou, E.; Attard, G.; Olmos, D.; Lee, J. Y.; Small, E. J.; Pereira de Santana Gomes, A. J.; Roubaud, G.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
    Journal Article

    Shadman, M.; Salkar, M.; Srivastava, B.; Karve, S.; Emond, B.; Gogna, P.; Manceur, A. M.; Lafeuille, M. H.; Rava, A.; Sun, H.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells
    Journal Article

    Munshi, M.; Liu, X.; Kofides, A.; Tsakmaklis, N.; Hunter, Z. R.; Guerrera, M. L.; Canning, A.; Gustine, J. N.; Liu, S.; Hatcher, J. M.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
    Review

    Stanchina, M. D.; Montoya, S.; Danilov, A. V.; Castillo, J. J.; Alencar, A. J.; Chavez, J. C.; Cheah, C. Y.; Chiattone, C.; Wang, Y.; Thompson, M.; more...
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Tyrosine kinase inhibitors with and without up-front stereotactic radiosurgery for brain metastases from EGFR and ALK oncogene-driven non-small cell lung cancer (TURBO-NSCLC)
    Journal Article

    Pike, L. R. G.; Miao, E.; Boe, L. A.; Patil, T.; Imber, B. S.; Myall, N. J.; Pollom, E. L.; Hui, C.; Qu, V.; Langston, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Progression-free survival and safety at 3.5 years of follow-up: Results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – A plain language summary
    Journal Article

    González-Martín, A.; Pothuri, B.; Vergote, I.; Graybill, W.; Lorusso, D.; McCormick, C. C.; Freyer, G.; Backes, F.; Heitz, F.; Redondo, A.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study assessing long-term response to ibrutinib monotherapy in recurrent or refractory CNS lymphoma
    Journal Article

    Grommes, C.; Nandakumar, S.; Schaff, L. R.; Gavrilovic, I.; Kaley, T. J.; Nolan, C. P.; Stone, J.; Thomas, A. A.; Tang, S. S.; Wolfe, J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): Current progress and latest advances
    Review

    Schaff, L.; Nayak, L.; Grommes, C.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • New means and challenges in the targeting of BTK
    Review

    Nawaratne, V.; Sondhi, A. K.; Abdel-Wahab, O.; Taylor, J.
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
    Journal Article

    Kato, T.; Yang, J. C. H.; Ahn, M. J.; Sakai, H.; Morise, M.; Chen, Y. M.; Han, J. Y.; Yang, J. J.; Zhao, J.; Hsia, T. C.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save